Therapeutic strategies to overcome cisplatin resistance in ovarian cancer
Author:
Funder
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Organic Chemistry,Drug Discovery,Pharmacology,General Medicine
Reference216 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA;Sung;Cancer. J. Clin.,2021
2. Cancer statistics, 2020, CA. Cancer;Siegel;J. Clin.,2020
3. Quantitative chemotherapeutic profiling of gynecologic cancer cell lines using approved drugs and bioactive compounds;Gorshkov;Transl. Oncol.,2018
4. FABP4 as a key determinant of metastatic potential of ovarian cancer;Gharpure;Nat. Commun.,2018
5. Cisplatin: the first metal based anticancer drug;Ghosh;Bioorg. Chem.,2019
Cited by 61 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Evaluation of erastin synergized cisplatin anti-nasopharyngeal carcinoma effect with a glutathione-activated near-infrared fluorescent probe;Chinese Chemical Letters;2024-02
2. LAMP2A regulates cisplatin resistance in colorectal cancer through mediating autophagy;2024-01-31
3. Inhibition of palmitoyltransferase ZDHHC12 sensitizes ovarian cancer cells to cisplatin through ROS‐mediated mechanisms;Cancer Science;2024-01-29
4. Exploiting the Warburg Effect: Co‐Delivery of Metformin and FOXK2 siRNA for Ovarian Cancer Therapy;Small Science;2024-01-29
5. Targeting PAK4 reverses cisplatin resistance in NSCLC by modulating ER stress;Cell Death Discovery;2024-01-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3